Aro Biotherapeutics is using their proprietary protein technology called Centyrins to address previously intractable diseases. Centyrins are small, engineered proteins derived from the human protein Tenascin C, a protein which is found in the extracellular matrix of tissues. By modifying the amino acid sequence of Centyrins, Aro has created a library of trillions of Centyrins variants that bind with high affinity and specificity against different antigens of interest. Aro is using this starting library to optimize Centyrins for desired tissue specificity. Once Centyrins have been optimized, they can be conjugated with drug payloads such as oligonucleotides. With this approach, Aro is pioneering a new class of tissue-targeted genetic medicines to treat disease.
Claim company profile to post jobs directly on this page and this website.